We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 4886D
Silence Therapeutics PLC
10 October 2018
Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro(TM)
October 10 2018
LONDON, Silence Therapeutics plc, (LON:SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms the receipt of a notice of intention to grant for a new European divisional patent, EP 3 222 724B, and further said that it has commenced a new cross-border interim injunction application in the Netherlands against Alnylam's Onpattro(TM) (patisiran).
Silence received a notice of intention to grant from the European Patent Office for patent application EP 3 222 724B, further strengthening its innovative chemical modification technology patent family in Europe, which sits at the heart of the current therapeutic siRNA field.
Silence has further filed a cross-border interim injunction application in the Netherlands (where Alnylam holds its Marketing Authorisation for Onpattro(TM)), requesting the courts to prohibit Alnylam from commercialising Onpattro(TM) across Europe until the resolution of the trial to determine infringement of EP 3 222 724B by Onpattro(TM). Despite requests not to do so, Alnylam has openly commercialised Onpattro(TM) in the face of the Silence claims. The Company therefore feels that it has been left with no alternative other than to take the necessary steps to enforce its patents and protect the historic investment made in its technology.
Onpattro(TM) remains accused of infringement of Silence European Patent EP 1 847 547B in the United Kingdom and Portugal and Silence is seeking injunctive relief in these territories to restrain Alnylam's infringement. The UK trial is to be held in December 2018, with a decision expected in early 2019. While Silence continues to protect its rights and inventions, the Company remains focused on executing its core business of drug discovery and development to continue to build its therapeutic pipeline.
David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:
"Silence continues to innovate with new, competitive RNAi medicines. During 2017 & 2018, the European Patent Office has upheld the validity of our expanding patent estate with the granting of additional patents around our foundational chemical modification IP.
When companies openly promote new product commercialisation in the face of relevant granted patent rights, Silence Therapeutics will take steps to enforce its patents and protect the historic investment made in its technology."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457 Dr David Horn Solomon, Chief Executive 6900 Officer David Ellam, Chief Financial Officer Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418 James Steel/Oliver Jackson 8900 European IR Tel: +44 (0) 20 Consilium Strategic Communications 3709 5700 Mary-Jane Elliott / Angela Gray silencetherapeutics@consilium-comms.com US IR Tel: +1 (212) 213-0006 Burns McClellan Lisa Burns, Jill Steier, John Grimaldi Silence.therapeutics@burnsmc.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCUGGWCUUPRPUB
(END) Dow Jones Newswires
October 10, 2018 02:00 ET (06:00 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions